Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis

Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis

<b>Background/Objectives</b>: Anlotinib is a novel oral antiangiogenic tyrosine kinase inhibitor (TKI) approved as a third-line treatment for advanced non-small-cell lung cancer (NSCLC). However, its efficacy in combination with docetaxel remains incompletely understood. Given the need f...

Full description

Saved in:
Bibliographic Details
Main Authors: Helal F. Hetta, Saleh F. Alqifari, Khaled Alshehri, Amirah Alhowiti, Saud S. Alharbi, Hyder Mirghani, Tariq Alrasheed, Mohamed E. A. Mostafa, Mohammed Sheikh, Mahmoud Elodemi, Sultan A. Alhumaid, Yasmin N. Ramadan, Noura H. Abd Ellah, Reem Sayad
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Pharmaceuticals
Subjects:
NSCLC
non-small-cell lung cancer
anlotinib
docetaxel
novel targeted drug
novel multi-targeting tyrosine kinase inhibitor
Online Access:https://www.mdpi.com/1424-8247/18/5/652
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items